Table 3.
IVF stimulation cycle outcomes in cancer vs. controls
| IVF parameters | Cancer n (%) ± sd 65 cycles | Control n (%) ± sd 122 cycles | p-value | |
|---|---|---|---|---|
| Protocol type | LDL | 39 (60.0) | 102 (83.6) | 0.0005 |
| Flare | 8 (12.3) | 11 (9.0) | 0.48 | |
| Antagonist | 18 (27.7) | 9 (7.4) | 0.0004 | |
| Ampules of gonadotropin | 38.0 ± 2.0 | 35.6 ± 1.5 | 0.28 | |
| Day of hCG administration | 11.7 ± 0.2 | 11.9 ± 0.1 | 0.15 | |
| Peak E2 | 2049.9 ± 133.5 | 2162.2 ± 71.7 | 0.21 | |
| Number of oocytes | 12.4 ± 7.8 | 10.9 ± 5.2 | 0.36 | |
| Insemination typea | Regular | 34 (57.6) | 111 (91.0) | <0.0001 |
| ICSI | 25 (42.4) | 11 (9.0) | <0.0001 | |
| Fertilization rate | Overall | 0.68 ± 0.3 | 0.74 ± 0.2 | 0.34 |
| ICSI | 0.77 ± 0.18 | 0.87 ± 0.18 | 0.052 | |
| Conventional | 0.71 ± 0.25 | 0.73 ± 0.18 | 0.33 | |
| Number of 2pn embryos | 6.6 ± 0.7 | 7.1 ± 0.4 | 0.11 | |
| Day of transferǂ | Cancer (n) | Control (fresh) (n) | 0.013 | |
| 2 | 2 | 8 | ||
| 3 | 15 | 72 | ||
| 5 | 0 | 42 | ||
aNot applicable for six patients who underwent oocyte cryopreservation
ǂIncomplete data for cancer patients